Suppr超能文献

蛋白激酶D3在L6肌管葡萄糖转运中的蛋白激酶C非依赖性作用。

Protein kinase C-independent effects of protein kinase D3 in glucose transport in L6 myotubes.

作者信息

Chen Jun, Lu Ganwei, Wang Q Jane

机构信息

Department of Pharmacology, University of Pittsburgh, E1354 Biomedical Science Tower, Pittsburgh, PA 15261, USA.

出版信息

Mol Pharmacol. 2005 Jan;67(1):152-62. doi: 10.1124/mol.104.004200. Epub 2004 Oct 20.

Abstract

Protein kinase C (PKC) and protein kinase D (PKD) coordinate and regulate many fundamental cellular processes. In this study, we evaluate the role of classic and novel PKC (c/nPKC) and PKD in glucose transport in L6 myotubes. c/nPKC is either activated by short-term phorbol 12-myristate 13-acetate (PMA) treatment or down-regulated by prolonged PMA treatment at a high dose in L6 myotubes. Our results indicate that PMA treatments have little impact on basal and insulin-stimulated glucose uptake and insulin-induced Akt activation. In contrast, the PKC inhibitors Go6976 [12-(2-cyanoethyl)-6,7,12,13-tetrahydro-13-methyl-5-oxo-5H-indolo[2,3-a]pyrrolo[3,4-c] carbazole], Go6983 [2-[1-(3-dimethylaminopropyl)-5-methoxyindol-3-yl]-3-(1H-indol-3-yl)maleimide], GF 109203X [bisindolylmaleimide I; 2-[1-(3-dimethylaminopropyl)indol-3-yl]-3-(1H-indol-3-yl)maleimide], and Ro 31-8220 [bisindolylmaleimide IX; 2-{1-[3-(amidinothio)propyl]-1H-indol3-yl}-3-(1-methylindol-3-yl)maleimide] block basal and insulin-stimulated glucose uptake, and their inhibitory effects persist upon down-regulation of c/nPKC by PMA, implying the presence of PKC-independent effectors in mediating their inhibition of glucose uptake. Go6976, the potent cPKC inhibitor that also effectively inhibits PKD, dose-dependently blocks basal glucose uptake in L6 myotubes, whereas Go6983, the nonselective PKC inhibitor that is ineffective for PKD, has little effect on basal glucose uptake, implying the involvement of PKD in this process. Most prominently, adenoviral gene expression of a dominant-negative PKD isoform, PKD3, primarily inhibits basal glucose uptake and, to a lesser extent, insulin-stimulated glucose uptake, whereas overexpression of wild-type PKD3 significantly enhances basal glucose uptake. Moreover, expression of a PKD3-targeted siRNA significantly inhibits basal glucose uptake. Taken together, our results indicate that PKD, specifically PKD3, directly contributes to insulin-independent basal glucose uptake in L6 skeletal muscle cells.

摘要

蛋白激酶C(PKC)和蛋白激酶D(PKD)协调并调节许多基本的细胞过程。在本研究中,我们评估了经典和新型PKC(c/nPKC)以及PKD在L6肌管葡萄糖转运中的作用。在L6肌管中,c/nPKC可通过短期佛波酯12-肉豆蔻酸13-乙酸酯(PMA)处理而被激活,或通过高剂量长时间PMA处理而下调。我们的结果表明,PMA处理对基础和胰岛素刺激的葡萄糖摄取以及胰岛素诱导的Akt激活影响很小。相反,PKC抑制剂Go6976 [12-(2-氰基乙基)-6,7,12,13-四氢-13-甲基-5-氧代-5H-吲哚并[2,3-a]吡咯并[3,4-c]咔唑]、Go6983 [2-[1-(3-二甲基氨基丙基)-5-甲氧基吲哚-3-基]-3-(1H-吲哚-3-基)马来酰亚胺]、GF 109203X [双吲哚基马来酰亚胺I;2-[1-(3-二甲基氨基丙基)吲哚-3-基]-3-(1H-吲哚-3-基)马来酰亚胺]和Ro 31-8220 [双吲哚基马来酰亚胺IX;2-{1-[3-(脒硫基)丙基]-1H-吲哚-3-基}-3-(1-甲基吲哚-3-基)马来酰亚胺]可阻断基础和胰岛素刺激的葡萄糖摄取,并且在PMA下调c/nPKC后其抑制作用仍然存在,这意味着在介导其对葡萄糖摄取的抑制作用中存在不依赖PKC的效应器。Go6976是一种有效的cPKC抑制剂,也能有效抑制PKD,它在L6肌管中剂量依赖性地阻断基础葡萄糖摄取,而Go6983是一种对PKD无效的非选择性PKC抑制剂,对基础葡萄糖摄取影响很小,这表明PKD参与了这一过程。最显著的是,显性负性PKD亚型PKD3的腺病毒基因表达主要抑制基础葡萄糖摄取,在较小程度上抑制胰岛素刺激的葡萄糖摄取,而野生型PKD3的过表达则显著增强基础葡萄糖摄取。此外,靶向PKD3的siRNA的表达显著抑制基础葡萄糖摄取。综上所述,我们的结果表明PKD,特别是PKD3,直接促进了L6骨骼肌细胞中不依赖胰岛素的基础葡萄糖摄取。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验